Therapeutic Asset Ratings
124 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Defactinib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
DEXAMETHASONE
Advanced Malignant Solid Neoplasm
M.D. Anderson Cancer Center
P2
CCC
(53)
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Ensartinib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Envafolimab
Advanced Malignant Solid Neoplasm
Yuanquan Yang
P2
CCC
(53)
EXEMESTANE
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P2
CCC
(53)
Gdc-0068
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
GSK-2636771
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Herzuma
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Larotrectinib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Neratinib Maleate
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Nilotinib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Osimertinib
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P2
CCC
(53)
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
PANITUMUMAB
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Relatlimab
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Selpercatinib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Shr-A1811
Advanced Malignant Solid Neoplasm
Haihua Yuan
P2
CCC
(53)
Siltuximab
Advanced Malignant Solid Neoplasm
Yuanquan Yang
P2
CCC
(53)
Sotorasib
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
su011248
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
TAMOXIFEN
Advanced Malignant Solid Neoplasm
OHSU Knight Cancer Institute
P2
CCC
(53)
Tas-102
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Telaglenastat
Advanced Malignant Solid Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Showing 51 to 75 of 124 assets
Previous
Page 3 of 5
Next